Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of AIV001 in Papulopustular Rosacea
NCT03883945Phase 2Withdrawn
- Sponsor
- AiViva BioPharma
- Start
- Jul 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of axitinib in papulopustular rosacea, sponsored by AiViva BioPharma. Planned start Jul 2021; status: withdrawn.
02
Drugs
axitinib
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT03883945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03883945.